Logo image of SKIN

BEAUTY HEALTH CO/THE (SKIN) Stock Fundamental Analysis

NASDAQ:SKIN - Nasdaq - US88331L1089 - Common Stock - Currency: USD

1.14  +0.11 (+10.68%)

Premarket: 1.15 +0.01 (+0.88%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to SKIN. SKIN was compared to 35 industry peers in the Personal Care Products industry. The financial health of SKIN is average, but there are quite some concerns on its profitability. SKIN is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SKIN had negative earnings in the past year.
In the past year SKIN had a positive cash flow from operations.
In the past 5 years SKIN reported 4 times negative net income.
In multiple years SKIN reported negative operating cash flow during the last 5 years.
SKIN Yearly Net Income VS EBIT VS OCF VS FCFSKIN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

SKIN's Return On Assets of -4.24% is on the low side compared to the rest of the industry. SKIN is outperformed by 65.71% of its industry peers.
SKIN has a Return On Equity of -56.17%. This is in the lower half of the industry: SKIN underperforms 68.57% of its industry peers.
Industry RankSector Rank
ROA -4.24%
ROE -56.17%
ROIC N/A
ROA(3y)-3.53%
ROA(5y)-10.89%
ROE(3y)-66.06%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SKIN Yearly ROA, ROE, ROICSKIN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

1.3 Margins

Looking at the Gross Margin, with a value of 60.25%, SKIN is in line with its industry, outperforming 48.57% of the companies in the same industry.
SKIN's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for SKIN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60.25%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.45%
GM growth 5YN/A
SKIN Yearly Profit, Operating, Gross MarginsSKIN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

4

2. Health

2.1 Basic Checks

SKIN does not have a ROIC to compare to the WACC, probably because it is not profitable.
SKIN has more shares outstanding than it did 1 year ago.
The debt/assets ratio for SKIN is higher compared to a year ago.
SKIN Yearly Shares OutstandingSKIN Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 50M 100M 150M
SKIN Yearly Total Debt VS Total AssetsSKIN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

SKIN has an Altman-Z score of 0.07. This is a bad value and indicates that SKIN is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of 0.07, SKIN is not doing good in the industry: 80.00% of the companies in the same industry are doing better.
The Debt to FCF ratio of SKIN is 59.12, which is on the high side as it means it would take SKIN, 59.12 years of fcf income to pay off all of its debts.
SKIN has a Debt to FCF ratio (59.12) which is in line with its industry peers.
SKIN has a Debt/Equity ratio of 10.66. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 10.66, SKIN is doing worse than 85.71% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 10.66
Debt/FCF 59.12
Altman-Z 0.07
ROIC/WACCN/A
WACC5.83%
SKIN Yearly LT Debt VS Equity VS FCFSKIN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 7.00 indicates that SKIN has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 7.00, SKIN belongs to the top of the industry, outperforming 97.14% of the companies in the same industry.
SKIN has a Quick Ratio of 5.99. This indicates that SKIN is financially healthy and has no problem in meeting its short term obligations.
SKIN has a Quick ratio of 5.99. This is amongst the best in the industry. SKIN outperforms 97.14% of its industry peers.
Industry RankSector Rank
Current Ratio 7
Quick Ratio 5.99
SKIN Yearly Current Assets VS Current LiabilitesSKIN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

4

3. Growth

3.1 Past

The earnings per share for SKIN have decreased strongly by -211.88% in the last year.
SKIN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -16.01%.
Measured over the past years, SKIN shows a quite strong growth in Revenue. The Revenue has been growing by 8.72% on average per year.
EPS 1Y (TTM)-211.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.29%
Revenue 1Y (TTM)-16.01%
Revenue growth 3Y8.73%
Revenue growth 5YN/A
Sales Q2Q%-13.74%

3.2 Future

SKIN is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -15.44% yearly.
The Revenue is expected to grow by 13.35% on average over the next years. This is quite good.
EPS Next Y-52.43%
EPS Next 2Y-7.36%
EPS Next 3Y-15.44%
EPS Next 5YN/A
Revenue Next Year-12.11%
Revenue Next 2Y-2.94%
Revenue Next 3Y3.33%
Revenue Next 5Y13.35%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SKIN Yearly Revenue VS EstimatesSKIN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 100M 200M 300M 400M 500M
SKIN Yearly EPS VS EstimatesSKIN Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 -0.5 -1 -1.5 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

SKIN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SKIN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SKIN Price Earnings VS Forward Price EarningsSKIN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

77.14% of the companies in the same industry are more expensive than SKIN, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 15.38
EV/EBITDA N/A
SKIN Per share dataSKIN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

SKIN's earnings are expected to decrease with -15.44% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-7.36%
EPS Next 3Y-15.44%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SKIN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BEAUTY HEALTH CO/THE

NASDAQ:SKIN (5/2/2025, 8:23:21 PM)

Premarket: 1.15 +0.01 (+0.88%)

1.14

+0.11 (+10.68%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)03-12 2025-03-12/amc
Earnings (Next)05-08 2025-05-08/amc
Inst Owners86.75%
Inst Owner Change-0.19%
Ins Owners8.64%
Ins Owner Change19.21%
Market Cap143.63M
Analysts48.57
Price Target1.61 (41.23%)
Short Float %7.09%
Short Ratio11.35
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.93%
Min EPS beat(2)20.82%
Max EPS beat(2)27.04%
EPS beat(4)4
Avg EPS beat(4)60.66%
Min EPS beat(4)20.82%
Max EPS beat(4)101.96%
EPS beat(8)7
Avg EPS beat(8)49.21%
EPS beat(12)11
Avg EPS beat(12)588.2%
EPS beat(16)12
Avg EPS beat(16)16.36%
Revenue beat(2)2
Avg Revenue beat(2)5.14%
Min Revenue beat(2)4.5%
Max Revenue beat(2)5.78%
Revenue beat(4)2
Avg Revenue beat(4)-0.11%
Min Revenue beat(4)-9.83%
Max Revenue beat(4)5.78%
Revenue beat(8)3
Avg Revenue beat(8)-2.14%
Revenue beat(12)7
Avg Revenue beat(12)1.96%
Revenue beat(16)11
Avg Revenue beat(16)5.38%
PT rev (1m)0%
PT rev (3m)-8.25%
EPS NQ rev (1m)2.88%
EPS NQ rev (3m)-38.08%
EPS NY rev (1m)6.84%
EPS NY rev (3m)-0.31%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-17.1%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-13.65%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.43
P/FCF 15.38
P/OCF 8.9
P/B 2.77
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.18
EYN/A
EPS(NY)-0.27
Fwd EYN/A
FCF(TTM)0.07
FCFY6.5%
OCF(TTM)0.13
OCFY11.23%
SpS2.65
BVpS0.41
TBVpS-0.95
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -4.24%
ROE -56.17%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60.25%
FCFM 2.79%
ROA(3y)-3.53%
ROA(5y)-10.89%
ROE(3y)-66.06%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.45%
GM growth 5YN/A
F-Score6
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 10.66
Debt/FCF 59.12
Debt/EBITDA N/A
Cap/Depr 23.05%
Cap/Sales 2.03%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7
Quick Ratio 5.99
Altman-Z 0.07
F-Score6
WACC5.83%
ROIC/WACCN/A
Cap/Depr(3y)42.98%
Cap/Depr(5y)45.87%
Cap/Sales(3y)3.35%
Cap/Sales(5y)3.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-211.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.29%
EPS Next Y-52.43%
EPS Next 2Y-7.36%
EPS Next 3Y-15.44%
EPS Next 5YN/A
Revenue 1Y (TTM)-16.01%
Revenue growth 3Y8.73%
Revenue growth 5YN/A
Sales Q2Q%-13.74%
Revenue Next Year-12.11%
Revenue Next 2Y-2.94%
Revenue Next 3Y3.33%
Revenue Next 5Y13.35%
EBIT growth 1Y47.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year117.36%
EBIT Next 3Y32.72%
EBIT Next 5Y34.66%
FCF growth 1Y7.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-25.82%
OCF growth 3YN/A
OCF growth 5YN/A